NCT06100900View on ClinicalTrials.gov

Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

BCX10013

Multiple dose levels may be tested in this study.

Trial Locations (4)

Unknown

BioCryst Investigative Site, Ampang

BioCryst Investigative Site, Bloemfontein

BioCryst Investigative Site, Cape Town

BioCryst Investigative Site, Pretoria

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY